臨床外科79巻9号

2024年09月発行

特集 徹底解説　大腸癌治療ガイドライン2024

詳説

切除不能大腸癌に対する導入薬物療法後の維持療法

著者： 若林宗弘¹ 谷口浩也²

所属機関： ¹東邦大学医療センター大森病院消化器内科 ²愛知県がんセンター薬物療法部

ページ範囲：P.1016 - P.1022

文献概要

【ポイント】
◆導入薬物療法後は毒性の低いレジメンによる維持療法によりQOLを維持しつつ病勢制御による生存期間延長をめざす．
◆オキサリプラチンによる末梢神経障害の軽減を目的として，“stop-and-go”レジメンが選択肢となる．
◆Doublet/triplet＋ベバシズマブ，またはdoublet＋抗EGFR抗体薬後の維持療法としてフッ化ピリミジン＋ベバシズマブ/抗EGFR抗体薬が選択肢となる．

参考文献

1）Maughan TS, James RD, Kerr DJ, et al：Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer：a multicentre randomised trial. Lancet 361：457-464, 2003

2）Labianca R, Sobrero A, Isa L, et al：Intermittent versus continuous chemotherapy in advanced colorectal cancer：a randomised ‘GISCAD' trial. Ann Oncol 22：1236-1242, 2011

3）Tournigand C, Cervantes A, Figer A, et al：OPTIMOX1：a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24：394-400, 2006

4）Chibaudel B, Maindrault-Goebel F, Lledo G, et al：Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27：5727-5733, 2009

5）Adams RA, Meade AM, Seymour MT, et al：Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer：results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12：642-653, 2011

6）Hochster HS, Grothey A, Hart L, et al：Improved time to treatment failure with an intermittent oxaliplatin strategy：results of CONcePT. Ann Oncol 25：1172-1178, 2014

7）Yalcin S, Uslu R, Dane F, et al：Bevacizumab ＋ capecitabine as maintenance therapy after initial bevacizumab ＋ XELOX treatment in previously untreated patients with metastatic colorectal cancer：phase III ‘Stop and Go' study results-a Turkish Oncology Group Trial. Oncology 85：328-335, 2013

8）Simkens LH, van Tinteren H, May A, et al：Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer（CAIRO3）：a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385：1843-1852, 2015

9）Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al：Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer（AIO 0207）：a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16：1355-1369, 2015

10）Manfredi S, Turpin A, Malka D, et al：Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer：The BEVAMAINT-PRODIGE 71—（FFCD 1710）phase III study. Dig Liver Dis 52：1143-1147, 2020

11）Berry SR, Cosby R, Asmis T, et al：Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer：a systematic review and meta-analysis. Ann Oncol 26：477-485, 2015

12）Adams R, Goey K, Chibaudel B, et al：Treatment breaks in first line treatment of advanced colorectal cancer：An individual patient data meta-analysis. Cancer Treat Rev 99：102226, 2021

13）Salvatore L, Bria E, Sperduti I, et al：Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer：A meta-analysis of individual patients' data from 3 phase III studies. Cancer Treat Rev 97：102202, 2021

14）Cremolini C, Loupakis F, Antoniotti C, et al：FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer：updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16：1306-1315, 2015

15）Cremolini C, Antoniotti C, Rossini D, et al：Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer（TRIBE2）：a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21：497-507, 2020

wild-type advanced colorectal cancer（COIN-B）：a randomised phase 2 trial. Lancet Oncol 15：631-639, 2014

17）Aranda E, García-Alfonso P, Benavides M, et al：First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer：Phase II randomised MACRO2 TTD study. Eur J Cancer 101：263-272, 2018

18）Cremolini C, Antoniotti C, Lonardi S, et al：Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer：A Randomized Phase 2 Clinical Trial. JAMA Oncol 4：529-536, 2018

19）Munemoto Y, Nakamura M, Takahashi M, et al：SAPPHIRE：a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer 119：158-167, 2019

Wild-Type Metastatic Colorectal Cancer：A Phase 2 Randomized Clinical Trial. JAMA Oncol 5：1268-1275, 2019

Wild-Type Metastatic Colorectal Cancer：The Randomized PANAMA Trial（AIO KRK 0212）. J Clin Oncol 40：72-82, 2022

wild-type（wt）metastatic colorectal cancer（mCRC）：An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study. J Clin Oncol 41：3571, 2023

23）Luo HY, Li YH, Wang W, et al：Single-agent capecitabine as maintenance therapy after induction of XELOX（or FOLFOX）in first-line treatment of metastatic colorectal cancer：randomized clinical trial of efficacy and safety. Ann Oncol 27：1074-1081, 2016

24）Adams RA, Fisher DJ, Graham J, et al：Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy：Results of the Randomized FOCUS4-N Trial. J Clin Oncol 39：3693-3704, 2021

25）Díaz-Rubio E, Gómez-España A, Massutí B, et al：First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer：the phase III MACRO TTD study. Oncologist 17：15-25, 2012

26）Koeberle D, Betticher DC, von Moos R, et al：Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer：a randomized phase III non-inferiority trial（SAKK 41/06）. Ann Oncol 26：709-714, 2015

wild-type metastatic colorectal cancer：Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study. Ann Oncol 33：S713-S714, 2022